Dr. Reddy’s Q1FY27 profit after tax drops 69% YoY to ₹4.44 billion; revenue falls 5.6% YoY to ₹80.71 billion
RDY•Q1FY27 results and margin pressure
Dr. Reddy’s posted Q1FY27 revenue of ₹80.71 billion, down 5.6% year over year; profit after tax attributable to equity holders fell 69% to ₹4.44 billion.
EBITDA dropped to ₹10.09 billion, with margin narrowing to 12.5% from 26.7% a year earlier.
Gross margin slid 10.4 percentage points to 46.5%, including a ₹2.4 billion provision tied to semaglutide API-related inventory and associated costs.
Regional performance and management commentary
North America revenue declined 35% year over year to ₹22.05 billion, while Emerging Markets climbed 31% to ₹18.33 billion.
Management flagged a transition beyond lenalidomide revenue, while highlighting double-digit underlying base-business growth and continued pipeline buildout in peptides and biosimilars.
